Background and objective: Standard nodal staging of lung cancer consists of positron emission tomography/ computed tomography (PET/CT), followed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) if PET/CT shows mediastinal lymphadenopathy. Sensitivity of EBUS-TBNA in patients with N0/N1 disease by PET/CT is unclear and largely based on retrospective studies. We assessed the sensitivity of EBUS-TBNA in this setting. Methods: We enrolled patients with proven or suspected lung cancer staged as N0/N1 by PET/CT and without metastatic disease (M0), who underwent staging EBUS-TBNA. Primary outcome was sensitivity of EBUS-TBNA compared with a composite reference standard of surgical stage or EBUS-TBNA stage if EBUS demonstrated N2/N3 disease. Results: Seventy-five patients were included in the analysis. Mean tumour size was 3.52 cm (AE1.63). Fifteen of 75 patients (20%) had N2 disease. EBUS-TBNA identified six while nine were only identified at surgery. Sensitivity of EBUS-TBNA for N2 disease was 40% (95% CI: 16.3-67.7%). Conclusion: A significant proportion of patients with N0/N1 disease by PET/CT had N2 disease (20%) and EBUS-TBNA identified a substantial fraction of these patients, thus improving diagnostic accuracy compared with PET/CT alone. Sensitivity of EBUS-TBNA however appears lower compared with historical data from patients with larger volume mediastinal disease. Therefore, strategies to improve EBUS-TBNA accuracy in this population should be further explored
INTRODUCTION
In the absence of distant metastases (M0), mediastinal nodal stage is a major determinant of treatment and prognosis 1 in patients with non-small cell lung cancer (NSCLC). Standard nodal staging is initially performed non-invasively with positron emission tomography/ computed tomography (PET/CT) followed by minimally invasive staging with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) when PET/CT is suggestive of mediastinal nodal involvement.
In patients without evidence of mediastinal nodal metastasis on PET/CT, the need for EBUS-TBNA
SUMMARY AT A GLANCE
We assessed the sensitivity of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients with lung cancer staged as N0/N1 by positron emission tomography/computed tomography (PET/CT). EBUS-TBNA improved the pretreatment staging of these patients compared with PET/CT; however, the sensitivity for N2 disease is only 40%, lower than sensitivities previously reported for N2/N3 patients.
becomes less clear. The most recent American College of Chest Physicians (ACCP) evidence-based guidelines 2 recommend minimally invasive mediastinal staging with a needle technique in patients with a central tumour or nodal hilar disease (N1) on PET/CT. This is based on the increased prevalence of N2 disease in this group, but this is a grade 1C recommendation, that is based on low quality evidence. In patients with peripheral tumours and no evidence of mediastinal or hilar nodal disease on PET/CT, invasive staging is not recommended in the guidelines.
Concerns have been raised regarding these recommendations given that the prevalence of occult nodal metastasis in patients with N0 disease by PET/CT appears to be higher than previously reported, with recent studies showing values as high as 17-22%. 3, 4 Furthermore, while mediastinal nodal staging is traditionally performed to rule out N2 disease and determine surgical eligibility, ruling out N1 disease is becoming increasingly relevant with the expanding use of stereotactic ablative radiotherapy (SABR).
Given the growing evidence that PET/CT may be insufficient for appropriate nodal staging, 5, 6 EBUS-TBNA may provide an attractive option to increase staging accuracy. Unfortunately, the sensitivity of EBUS-TBNA in patients with a normal mediastinum (N0 or N1) by PET/CT is not clearly defined and is largely based on retrospective studies. We conducted a prospective study to determine the sensitivity and negative predictive value (NPV) of EBUS-TBNA for detecting N2 or N3 disease in this population. Additionally, we estimated the concordance of PET/CT stage with EBUS-TBNA stage to assess the added value of EBUS/ TBNA and describe the performance of EBUS to identify N1 disease in the subgroup of clinical N0 patients
METHODS

Study design
This was a prospective cohort study of consecutive patients with early stage NSCLC undergoing EBUS-TBNA for mediastinal staging prior to definitive treatment. The protocol was approved by the Institutional Review Board (IRB protocol number 2007-0387). Written informed consent was obtained from all participants for both the clinical procedure and the study at the time of enrolment.
Patient selection
Subjects were eligible if they met all the following criteria: (i) ≥18 years old, (ii) Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, (iii) proven or suspected NSCLC, (iv) full radiographic work-up including contrast-enhanced CT scan of the chest and a PET/CT within a month of the scheduled procedure and (v) believed to be surgically resectable after initial clinical staging (N0 or N1 with no distant metastasis). If the patient was a survivor from a prior malignancy, inclusion also required a history of treatment with curative intent and no evidence of active or recurrent disease for the prior 5 years.
Patients who met any of the following criteria were not eligible: (i) contraindication for EBUS-TBNA such as bleeding diathesis, (ii) prior chemotherapy or radiation therapy for a thoracic malignancy, (iii) separate tumours with the same histology (where primary vs metastatic disease was unclear) and (iv) women who were pregnant or lactating.
Imaging tests
Lymph node enlargement by CT criteria was defined as size >1 cm on short axis. Standardized uptake values (SUV) ≥ 2.5 on PET/CT defined an Fluorodeoxyglucose (FDG)-avid lymph node. A tumour was defined as central if it was located within the inner third of the hemithorax and as peripheral if it was in the outer two thirds of the hemithorax.
In the few cases where there was a discrepancy between the interventional pulmonologist and the radiologist regarding the radiological stage by PET/CT, radiological stage was assigned by two of the investigators who were unaware of the final pathological stage.
Endobronchial ultrasound-guided transbronchial needle aspiration EBUS-TBNA was performed with a convex probe bronchoscope as previously described. 7 Briefly, with the patient under general anaesthesia, the bronchoscope was introduced and the intrathoracic lymph node stations were systematically examined to identify those meeting ultrasound criteria for sampling. These criteria included short axis diameter ≥ 0.5 cm and/or a combination of features associated with malignancy (e.g. sharp margins, heterogeneity, central necrosis sign, absence of a central hilar structure and rounded shape). Nodal sampling was performed beginning at the contralateral hilum and moving towards the N1 nodes. Using a 22-gauge needle, at least three passes were performed at each station sampled. Rapid onsite cytological evaluation (ROSE) was available for all procedures. Adequate sample was defined by the presence of granulomas, malignancy or lymphocytes if the more cellular areas of direct smears contained at least 40 lymphocytes per high power field (i.e. 400× magnification). The lymph node stations were described according to the International Association for the Study of Lung Cancer classification.
Outcome measures
Our primary outcome was the sensitivity of EBUS-TBNA for N2 disease in patients with early stage NSCLC using a composite gold standard of either final pathological stage or EBUS-TBNA stage if EBUS-TBNA showed N2 disease or higher. To assess the added value of EBUS-TBNA, we also estimated the concordance rate of the N descriptor between PET/CT and EBUS-TBNA.
used to compare continuous variables and chi-square tests were used to compare categorical variable. A Pvalue of <0.05 was considered statistically significant. All analyses were performed using STATA software (version 13.0; SAS Institute, Cary, NC, USA).
RESULTS
Patients
From April 2009 through February 2014, we consented a total of 120 participants. Eventually, 45 patients were excluded ( Fig. 1 ): 10 were excluded because they did not meet eligibility criteria based on further imaging studies or additional review of prior images demonstrating more advanced disease; 6 patients were found to have a diagnosis other than NSCLC, 3 by EBUS-TBNA and 3 at the time of surgery; and 29 patients did not undergo lymphadenectomy despite having N0 or N1 disease on EBUS-TBNA. A total of 75 patients had a reference standard allowing us to assess the primary outcome of EBUS-TBNA sensitivity.
Among these 75 patients, the mean age was 66.3 years (AE9.6), with 49% males. Mean size of the tumour on CT was 3.52 cm (AE1.63), and 29% were centrally located. The majority of patients had clinical N0 disease (81%). Baseline characteristics are depicted in Table 1 .
Endobronchial ultrasound-guided transbronchial needle aspiration
The characteristics of the biopsied lymph nodes and sample adequacy among these are shown in Table 2 . There were no complications from EBUS-TBNA.
Overall, 23 of 75 (30%) patients were eventually upstaged, with 15 of 75 (20%) found to have N2 disease or higher (Fig. 2) . EBUS-TBNA identified six of these while the other nine were only identified at surgery. Median time from EBUS-TBNA to surgery was 19 days (interquartile range (IQR): 11-28). Sensitivity of EBUS-TBNA for N2 disease among all evaluated patients compared with the reference standard was 40% (95% CI: 16.3-67.7%) with an NPV of 89.9% (76.7-93.9). Among the patients with EBUS-accessible nodal disease, defined as stations 1, 2, 4, 3P, 7, 10 and 11, the sensitivity was 54.5% (95% CI: 23.4-83.2), and the NPV was 92.3% (95% CI: 84-98). Test characteristics are shown in Table 3 .
The proportion of patients concordantly staged as less than N2 with both PET/CT and EBUS-TBNA was 92% (95% CI: 83.4-97.0%). After performing an EBUS-TBNA, the probability of having occult N2 disease was reduced from 20% (15/75) to 12% (9/75). In other words, the number of patients needing to undergo an EBUS-TBNA in order to avoid one case of N2 disease or higher being discovered at surgery would be 12.5.
The characteristics of patients with occult N2 disease are shown in Table 4 . On bivariate analyses, there were no statistically significant differences between patients with or without occult lymph node disease regarding age, tumour size and histology or tumour location.
Subgroup of clinical N0 patients
Among the patients who had clinical N0 disease (n = 61), 22 (36%) were eventually found to have nodal metastasis, 12 were upstaged to N1 (19%) and 10 were upstaged to N2 disease (16%) (Fig. 2) .Of the 10 patients upstaged to N2, 5 had peripheral tumours (Table 4) .
Of the 12 patients upstaged to N1, only one patient was identified by EBUS-TBNA. Of the 11 patients with false negatives, 8 were from intraparenchymal lymph nodes not accessible by EBUS-TBNA, 1 was sampled and adequate lymphoid tissue was obtained and 2 were not sampled because they did not meet size or morphological criteria for sampling. Of the 10 patients upstaged to N2 disease or higher, only 2 were identified by EBUS. Of the eight patients with false negatives, four were located in stations not accessible by EBUS-TBNA, three were not sampled because they did not 
Subgroup of clinical N1 patients
Fourteen patients had clinical N1 disease. Five of the 14 (36%) patients were eventually upstaged to N2 disease, 4 were confirmed as N1 and the remaining 5 were downstaged to N0. Of the five patients upstaged from clinical N1 to N2, four (80%) were identified by EBUS-TBNA. The only false negative was at a subcarinal lymph node where adequate lymphocytes were obtained. Of the four patients eventually confirmed as N1 disease, three had been wrongly downstaged by EBUS-TBNA. Two of these three patients were located in stations not accessible by EBUS (intralobar); and on the one remaining patient, adequate lymphocytes were obtained.
The sensitivity of EBUS-TBNA for N2 disease was not statistically different in the clinical N0 group (20%, 95% CI: 2.52-55.6) compared with the clinical N1 group (80%, 95% CI: 28.4-99.5).
DISCUSSION
In this prospective study of patients with NSCLC and no evidence of mediastinal nodal metastasis on PET/CT, we found that EBUS-TBNA has a sensitivity of 40% in the identification of N2 disease. While the sensitivity is lower than previously reported, these findings also suggest that EBUS-TBNA can improve the preoperative staging of these patients compared with standard radiographic staging with PET/CT, given the 92% concordance rate.
A surprising 20% of patients with N0 or N1 disease by clinical radiographic criteria were found to have occult N2 disease. As expected, patients with clinical N1 disease had a higher rate of occult N2 disease (36%), and EBUS-TBNA detected 80% of them. Occult N2 disease was present not only among those with central tumours or N1 disease, but also in 5 of 61 (8%) patients with N0 disease and peripheral tumours, a group where the current ACCP guidelines do not recommend any form of preoperative lymph node sampling. These findings may have important implications in clinical management particularly if SABR is being considered.
Additionally, EBUS-TBNA was useful in identifying diagnosis other than NSCLC that did not require surgery as the first choice of treatment (3 of 110 eligible patients). These patients in addition to those found to have N2 disease (six patients) compose a group of patients in whom an unnecessary thoracotomy was avoided.
The sensitivity of EBUS-TBNA in this study is lower than described in the setting of larger volume mediastinal disease 2 and consistent with more recent studies in similar populations that reported sensitivities around 35%. 3, 8 The lower sensitivity is at least partially explained by lymph nodes in locations not accessible to EBUS-TBNA and possibly the presence of small volume metastasis in lymph nodes without ultrasound features of malignancy. The generalizability of our findings may be limited by the fact that the procedures were all performed under general anaesthesia, with ROSE availability and in a high-volume centre. Also, a substantial number of enrolled patients eventually elected to undergo treatments other than surgery and as such did not have a surgical confirmation. As these patients were excluded from the primary outcome analysis, this may have introduced bias into our sensitivity estimate.
The strengths of this study include the prospective collection of data and that the imaging was always obtained within a month of undergoing an EBUS-TBNA, and surgery was performed generally within 30 days of the EBUS-TBNA, reducing the time window for interval nodal upstaging.
Although initial studies on the sensitivity of EBUS in this population were higher, 9 this study adds to the growing body of evidence demonstrating that EBUS-TBNA may have only a moderate sensitivity in this setting and raises the possibility that the diagnostic utility of EBUS may be different in the clinical N0 and N1 groups. A recent report has even suggested that among the patients with cN1 disease and negative N2 nodes on EBUS-TBNA, a mediastinoscopy may also be considered to rule out N2 disease. 8 As some of the false negative results in this particular study were from lymph nodes that did not meet current size thresholds for biopsy, our results suggest possible alterations in the current sampling protocols in this patient population including modifying the currently used size threshold for biopsy, systematic sampling of stations 4 and 7 regardless of size, sampling multiple lymph nodes at each station, lymph node elastography, combined EBUS and oesophageal ultrasound or perhaps even incorporating the use of genomic, proteomic or other more sensitive biomarkers for biopsy sample analysis. Whether a more thorough sampling of the mediastinal lymph nodes in this setting, as suggested by some investigators, 10 would improve the accuracy of staging with TBNA is unknown but should be the subject of future studies.
The combined EBUS-EUS strategy for nodal staging was examined in a recent meta-analysis, showing a modest increase in sensitivity. 11 These findings were largely based on a population with standard guideline recommended indications for invasive mediastinal staging based on either abnormal lymph nodes or central tumours. In our study, only one of the patients eventually diagnosed with N2 disease involved a lymph node accessible exclusively by Endoscopic Ultrasound (EUS) (station 9) but not by EBUS-TBNA.
The best staging strategy in terms of accuracy, costeffectiveness and safety in the setting of negative results on PET/CT is currently unclear and should also be the subject of further investigation. Given the limitations of various testing modalities, it is unlikely to be a single definitive test but rather a composite estimate based on an assessment of the pretest probability, minimally invasive sampling and the possible consequence of missed nodal disease.
In conclusion, the prevalence of occult mediastinal nodal metastasis can be as high as 20% in patients with a radiographically normal mediastinum by PET/CT. -EBUS-TBNA may be useful in identifying up to 40% of these patients and should be considered in this setting particularly in patients with clinical N1 disease.
